Elutia Partners With Vizient To Expand Access To EluPro™

Elutia Inc., a leader in drug-eluting biomatrix products, has announced a new agreement with Vizient to provide its innovative EluPro™ Antibiotic Eluting BioEnvelope to Southern Strategic Sourcing Partners (S3P). This partnership will give S3P’s network of 993 acute care facilities access to EluPro starting immediately. EluPro is the first antibiotic-eluting biologic envelope approved by the U.S. Food and Drug Administration (FDA) for cardiac implantable electronic devices (CIEDs) and neurostimulators. 

Dr. Randy Mills, Chief Executive Officer of Elutia, said in a statement, “We are excited to partner with S3P to expand access to EluPro, our innovative solution for preventing post-surgical device complications. This marks a pivotal milestone as we secure our second major GPO partnership ahead of EluPro’s full commercial launch later this month. With SP3’s extensive network spanning over a dozen U.S. states, this collaboration significantly accelerates our mission to deliver life-changing technology to more patients, empowering them to heal and thrive without compromise.”

EluPro consists of potent antibiotics with a biodegradable extracellular matrix that regenerates into the patient’s tissue, thus reducing post-surgical infection, migration, and skin breakage. This is an innovative solution for both patients and healthcare providers. S3P is a prominent healthcare supply chain comprising 91 health systems and managing over $4 billion in annual spending across 993 acute care facilities.